Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
Matching Trials
For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.
| NCT05870748 | II/III | Platinum resistant FOLR+ high grade serous ovarian cancer with prior bevacizumab (Phase III) | REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) | AZ, CA, DC, FL, MD, MA, MN, NE, NM, NY, OH, OK, OR, PA, TX, VA | View Drugs | View Results |
| Luveltamab tazevibulin | STRO-002, anti-folate receptor-alpha antibody drug conjugate STRO-002 | ADC: anti-FRalpha + microtubule destabilizer (SC209) | Clinical Trials | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
